Lyell Immunopharma is a strong investment opportunity due to its successful clinical trials and potential market opportunities, strong leadership and manufacturing capabilities, and promising potential for further advancements in CAR-T therapy.
Bears say
Lyell Immunopharma is facing significant competition in the highly competitive and rapidly evolving field of cell therapies for cancer. Additionally, the company's financials also highlight potential concerns, with a net loss of $94 million in 2020, a decrease in cash and cash equivalents, and no revenue. Lastly, the success of the company's product candidates heavily relies on the outcome of ongoing clinical trials, which may be subject to delays and failures.
Lyell Immunopharma (LYEL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Lyell Immunopharma (LYEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.
According to 6 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $37.17, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $37.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Lyell Immunopharma (LYEL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.